Tortugas Neurosciences debuted with $106 million and a clinical pipeline aimed at brain and neuropsychiatric disorders. The company is led by veterans from Sage Therapeutics and is building around in-licensed oral small molecules for schizophrenia and tinnitus, alongside additional neurology assets in development.